Cogent Biosciences Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, Cogent Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $55.82. The average 1-year stock price forecast is 74.33% higher than the current stock price, while the lowest is $45 (+40.54%) and the highest is $62 (+93.63%).

Price Target: $55.82 (+74.33%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$45	$55.82	$55	$62
Change	+40.54%	+74.33%	+71.77%	+93.63%

Analyst Ratings

The average analyst rating for Cogent Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Apr '26	May '26	Jun '26	Jul '26	Aug '26	Sep '26
Strong Buy	9	9	9	9	9	9
Buy	2	2	2	2	2	2
Hold	2	2	2	2	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	13	13	13	13	12	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
David Nierengarten Wedbush	Wedbush	Buy Maintains $55	Buy	Maintains	$55	+71.77%	Sep 16, 2026
Sam Slutsky LifeSci Capital	LifeSci Capital	Buy Maintains $55	Buy	Maintains	$55	+71.77%	Sep 15, 2026
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Reiterates $55	Buy	Reiterates	$55	+71.77%	Sep 15, 2026
Anupam Rama J.P. Morgan	J.P. Morgan	Buy Maintains $62	Buy	Maintains	$62	+93.63%	Sep 9, 2026
Allison Bratzel Piper Sandler	Piper Sandler	Buy Maintains $52 → $55	Buy	Maintains	$52 → $55	+71.77%	Aug 17, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

5.99M

Revenue Next Year

292.82M

from 5.99M

4,789.59%

from 5.99M

EPS This Year

-2.21

from -2.11

EPS Next Year

-1.11

from -2.21

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	5.99M
Operating Income	-75.55M	-147.84M	-208.13M	-275.94M	-333.36M	-415.54M
Net Income	-72.27M	-140.24M	-192.41M	-255.86M	-328.94M	-398.94M
EPS	-	-	-	-	-2.11	-2.21
Free Cash Flow	-	-	-	-	-266.00M	-312.00M
No. Analysts	-	-	-	-	-	11

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	13.8M
Avg	6.0M
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	6,463.9%
Avg	4,789.6%
Low	2,241.4%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-1.92
Avg	-2.21
Low	-2.54

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-